Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109406 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02109406 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT02109406, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days), three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and safety of two dose levels of a dual pharmacology molecule with the combined properties of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA); (AZD2115) delivered by a metered-dose inhaler (MDI) in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo MDI
- DRUG AZD2115 Dose 1
- DRUG AZD 2115, Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109406
The ClinicalTrials.gov registry entry for NCT02109406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo MDI is the first listed.
NCT02109406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109406 about?
NCT02109406 is a clinical study titled "Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD". This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days), three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and safety of two dose levels of a dual pharmacology molecule with the combined properties of a long-acting muscarinic antagon...
What is the current status of trial NCT02109406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02109406?
The interventions under investigation include: Placebo MDI (DRUG), AZD2115 Dose 1 (DRUG), AZD 2115, Dose 2 (DRUG).
Who is sponsoring clinical trial NCT02109406?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.